doi: 10.1016/j.thromres.2017.07.032.
Epub 2017 Aug 1.
The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients
Affiliations
- PMID: 28802144
- DOI: 10.1016/j.thromres.2017.07.032
Item in Clipboard
The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients
Thromb Res.
2017 Oct.
No abstract available
Keywords: CYP2C19; Clopidogrel; Coronary artery disease patients; Dual antiplatelet therapy (DAPT); High on treatment platelets reactivity; VerifyNow.
Similar articles
-
Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.Eur J Clin Pharmacol. 2014 Jun;70(6):667-73. doi: 10.1007/s00228-014-1672-3. Epub 2014 Apr 26. Eur J Clin Pharmacol. 2014. PMID: 24763934 Clinical Trial.
-
Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients.Braz J Med Biol Res. 2017 Jan 9;50(1):e5660. doi: 10.1590/1414-431X20165660. Braz J Med Biol Res. 2017. PMID: 28076455 Free PMC article.
-
Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.PLoS One. 2014 Oct 16;9(10):e110188. doi: 10.1371/journal.pone.0110188. eCollection 2014. PLoS One. 2014. PMID: 25329996 Free PMC article.
-
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].Kardiologiia. 2010;50(6):4-21. Kardiologiia. 2010. PMID: 20659022 Review. Russian.
-
Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.Thromb Res. 2015 Mar;135(3):449-58. doi: 10.1016/j.thromres.2014.12.007. Epub 2014 Dec 9. Thromb Res. 2015. PMID: 25511576 Review.
Cited by
-
METTL3-mediated methylation of CYP2C19 mRNA may aggravate clopidogrel resistance in ischemic stroke patients.Open Med (Wars). 2024 Feb 7;19(1):20240899. doi: 10.1515/med-2024-0899. eCollection 2024. Open Med (Wars). 2024. PMID: 38463525 Free PMC article.
-
The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing.Cardiovasc Drugs Ther. 2024 Jan 15. doi: 10.1007/s10557-024-07544-6. Online ahead of print. Cardiovasc Drugs Ther. 2024. PMID: 38224415
-
The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention.Front Cardiovasc Med. 2023 Feb 8;9:1027892. doi: 10.3389/fcvm.2022.1027892. eCollection 2022. Front Cardiovasc Med. 2023. PMID: 36843628 Free PMC article.
-
The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD).Molecules. 2021 Apr 1;26(7):1987. doi: 10.3390/molecules26071987. Molecules. 2021. PMID: 33915807 Free PMC article. Review.
-
Cyp2C19*2 Polymorphism Related to Clopidogrel Resistance in Patients With Coronary Heart Disease, Especially in the Asian Population: A Systematic Review and Meta-Analysis.Front Genet. 2020 Dec 22;11:576046. doi: 10.3389/fgene.2020.576046. eCollection 2020. Front Genet. 2020. PMID: 33414804 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
